Extended Stability of Reconstituted Lyophilized Erwinia L-asparaginase in Vials
| Autor: | Hector Gonzalez-Mendez, Fernando Gutiérrez-Nicolás, Javier F Merino-Alonso, Macarena Gonzalez-Cruz, Ivette Mourani-Padron, Ruth Ramos-Díaz, Jesica Diaz-Vera, Gloria Julia Nazco-Casariego, Micaela M ViÑa-Romero |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Pharmacology
Cancer Research Chromatography biology Chemistry Lymphoblastic Leukemia Temperature Antineoplastic Agents Precursor Cell Lymphoblastic Leukemia-Lymphoma Erwinia biology.organism_classification Vial General Biochemistry Genetics and Molecular Biology L asparaginase Erwinia l-asparaginase 03 medical and health sciences 0302 clinical medicine 030220 oncology & carcinogenesis Asparaginase Humans Child Research Article |
| Zdroj: | In Vivo |
| ISSN: | 1791-7549 0258-851X |
| DOI: | 10.21873/invivo.12055 |
| Popis: | Background/aim L-Asparaginase (L-ASNase) is used as a tumor-inhibitory drug on paediatric acute lymphoblastic leukemia (ALL). ERW-ASNase is commercialised as a lyophilized powder stable only for 8 hours once reconstituted and, consequently, the leftover is usually discarded. The aim of this study will be to analyse the stability of the reconstituted lyophilised ERW-ASNase. Materials and methods In the present study, we analysed the enzymatic stability of reconstituted ERW-ASNase after conservation in three different temperature conditions for 2 and 5 days. Results Our results show that ERW-ASNase is stable at 4°C, -20°C and -80°C for up to 5 days, retaining 95% of the initial enzymatic activity in all three storage temperatures tested. Conclusion It is feasible to reuse the remaining content of ERW-ASNase vial after reconstitution, which allows the optimization of the content of ERW-ASNase vials use and reduces the cost of this formulation usage, making it more accessible. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|